RxSight (RXST) Competitors $9.31 -0.11 (-1.17%) Closing price 04:00 PM EasternExtended Trading$9.28 -0.03 (-0.32%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXST vs. NVCR, SSII, CDRE, BLFS, ESTA, MDXG, PLSE, INMD, IRMD, and BBNXShould you be buying RxSight stock or one of its competitors? The main competitors of RxSight include NovoCure (NVCR), SS Innovations International (SSII), Cadre (CDRE), BioLife Solutions (BLFS), Establishment Labs (ESTA), MiMedx Group (MDXG), Pulse Biosciences (PLSE), InMode (INMD), iRadimed (IRMD), and Beta Bionics (BBNX). These companies are all part of the "medical equipment" industry. RxSight vs. Its Competitors NovoCure SS Innovations International Cadre BioLife Solutions Establishment Labs MiMedx Group Pulse Biosciences InMode iRadimed Beta Bionics RxSight (NASDAQ:RXST) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation. Does the media refer more to RXST or NVCR? In the previous week, RxSight had 29 more articles in the media than NovoCure. MarketBeat recorded 43 mentions for RxSight and 14 mentions for NovoCure. NovoCure's average media sentiment score of 1.39 beat RxSight's score of 0.43 indicating that NovoCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 5 Very Positive mention(s) 1 Positive mention(s) 34 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral NovoCure 10 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, RXST or NVCR? RxSight has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Is RXST or NVCR more profitable? RxSight has a net margin of -21.93% compared to NovoCure's net margin of -27.13%. RxSight's return on equity of -11.56% beat NovoCure's return on equity.Company Net Margins Return on Equity Return on Assets RxSight-21.93% -11.56% -10.31% NovoCure -27.13%-47.74%-13.79% Which has preferable valuation & earnings, RXST or NVCR? RxSight has higher earnings, but lower revenue than NovoCure. RxSight is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRxSight$139.93M2.72-$27.45M-$0.80-11.64NovoCure$605.22M2.24-$168.63M-$1.56-7.79 Do insiders & institutionals have more ownership in RXST or NVCR? 78.8% of RxSight shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 9.6% of RxSight shares are held by insiders. Comparatively, 5.5% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend RXST or NVCR? RxSight currently has a consensus price target of $10.00, suggesting a potential upside of 7.41%. NovoCure has a consensus price target of $28.79, suggesting a potential upside of 136.92%. Given NovoCure's stronger consensus rating and higher possible upside, analysts clearly believe NovoCure is more favorable than RxSight.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RxSight 2 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.92NovoCure 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 SummaryRxSight beats NovoCure on 9 of the 16 factors compared between the two stocks. Get RxSight News Delivered to You Automatically Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXST vs. The Competition Export to ExcelMetricRxSightMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$380.97M$6.79B$5.79B$10.15BDividend YieldN/A1.23%5.69%4.61%P/E Ratio-11.6425.5274.5925.92Price / Sales2.7262.89454.0285.55Price / CashN/A21.6337.0859.91Price / Book1.335.0012.156.29Net Income-$27.45M$176.38M$3.28B$270.85M7 Day Performance4.72%1.00%0.98%3.35%1 Month Performance26.67%3.19%7.20%6.40%1 Year Performance-82.93%12.30%63.06%28.21% RxSight Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXSTRxSight1.8679 of 5 stars$9.31-1.2%$10.00+7.4%-82.7%$380.97M$139.93M-11.64220Trending NewsNVCRNovoCure4.3661 of 5 stars$12.60+2.6%$28.79+128.5%-26.1%$1.37B$605.22M-8.081,488Positive NewsGap UpSSIISS Innovations InternationalN/A$6.14-12.3%N/AN/A$1.36B$20.65M0.004Gap DownHigh Trading VolumeCDRECadre2.8521 of 5 stars$31.83-0.5%$31.50-1.0%-5.7%$1.30B$567.56M33.862,284Positive NewsBLFSBioLife Solutions2.8073 of 5 stars$26.22-0.9%$31.29+19.3%+15.3%$1.27B$93.47M-218.48440Positive NewsESTAEstablishment Labs2.2931 of 5 stars$38.24-2.0%$56.50+47.8%-7.8%$1.13B$166.02M-12.541,018Positive NewsMDXGMiMedx Group3.4983 of 5 stars$7.17+0.4%$12.00+67.4%+15.3%$1.06B$348.88M34.14870Positive NewsPLSEPulse Biosciences4.13 of 5 stars$15.04-0.5%$22.00+46.3%-11.9%$1.02B$700K-14.32140Positive NewsINMDInMode3.1199 of 5 stars$15.28+2.0%$18.04+18.1%-9.2%$946.87M$401.56M6.19480Positive NewsIRMDiRadimed4.8134 of 5 stars$71.85-0.2%$72.00+0.2%+58.9%$915.36M$73.24M44.35110Short Interest ↓BBNXBeta Bionics1.075 of 5 stars$23.13+14.5%$22.56-2.5%N/A$878.10M$65.12M0.00294High Trading Volume Related Companies and Tools Related Companies NovoCure Alternatives SS Innovations International Alternatives Cadre Alternatives BioLife Solutions Alternatives Establishment Labs Alternatives MiMedx Group Alternatives Pulse Biosciences Alternatives InMode Alternatives iRadimed Alternatives Beta Bionics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXST) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RXST Stock Alerts